Wall Street Zen Upgrades Kewaunee Scientific (NASDAQ:KEQU) to Buy

Kewaunee Scientific (NASDAQ:KEQU - Get Free Report) was upgraded by analysts at Wall Street Zen from a "hold" rating to a "buy" rating in a research note issued to investors on Saturday.

Kewaunee Scientific Price Performance

NASDAQ KEQU opened at $58.94 on Friday. The company has a current ratio of 2.20, a quick ratio of 1.54 and a debt-to-equity ratio of 0.92. The company has a fifty day simple moving average of $39.60 and a 200 day simple moving average of $47.70. The company has a market cap of $167.39 million, a P/E ratio of 15.39 and a beta of 0.70. Kewaunee Scientific has a 1 year low of $30.33 and a 1 year high of $71.33.

Kewaunee Scientific (NASDAQ:KEQU - Get Free Report) last posted its quarterly earnings data on Wednesday, June 25th. The technology company reported $1.95 earnings per share (EPS) for the quarter. The business had revenue of $77.15 million during the quarter. Kewaunee Scientific had a net margin of 4.74% and a return on equity of 26.02%.

Insider Buying and Selling at Kewaunee Scientific

In related news, CEO Thomas David Hull III sold 1,844 shares of the company's stock in a transaction on Monday, April 14th. The shares were sold at an average price of $32.44, for a total transaction of $59,819.36. Following the completion of the sale, the chief executive officer directly owned 36,072 shares of the company's stock, valued at approximately $1,170,175.68. This represents a 4.86% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Donald T. Gardner III sold 3,000 shares of the company's stock in a transaction on Wednesday, April 9th. The stock was sold at an average price of $37.75, for a total transaction of $113,250.00. Following the sale, the chief financial officer directly owned 15,358 shares of the company's stock, valued at approximately $579,764.50. This represents a 16.34% decrease in their ownership of the stock. The disclosure for this sale can be found here. 14.20% of the stock is currently owned by corporate insiders.

Institutional Trading of Kewaunee Scientific

Several large investors have recently modified their holdings of KEQU. Invesco Ltd. bought a new stake in Kewaunee Scientific in the 4th quarter valued at $6,545,000. American Century Companies Inc. boosted its holdings in Kewaunee Scientific by 43.4% in the 1st quarter. American Century Companies Inc. now owns 49,182 shares of the technology company's stock valued at $1,937,000 after purchasing an additional 14,889 shares during the period. O Shaughnessy Asset Management LLC boosted its holdings in Kewaunee Scientific by 3.3% in the 4th quarter. O Shaughnessy Asset Management LLC now owns 28,008 shares of the technology company's stock valued at $1,733,000 after purchasing an additional 891 shares during the period. Punch & Associates Investment Management Inc. bought a new stake in Kewaunee Scientific in the 1st quarter valued at $788,000. Finally, Goldman Sachs Group Inc. boosted its holdings in Kewaunee Scientific by 125.7% in the 1st quarter. Goldman Sachs Group Inc. now owns 19,397 shares of the technology company's stock valued at $764,000 after purchasing an additional 10,803 shares during the period. 32.69% of the stock is owned by institutional investors.

About Kewaunee Scientific

Kewaunee Scientific Corporation designs, manufactures, and installs laboratory, healthcare, and technical furniture and infrastructure products. The company operates through two segments, Domestic and International. Its products include steel and wood casework, fume hoods, adaptable modular systems, moveable workstations, stand-alone benches, biological safety cabinets, and epoxy resin work surfaces and sinks.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.